Abstract-We analyzed the genetic defect in a 67-year-old Japanese male patient with apolipoprotein (apo) A-I and high density lipoprotein (HDL) deficiencies, corneal opacities, and coronary artery disease. The plasma concentrations of apoA-I and HDL cholesterol were 2.9 to 7.3 mg/dL and 0.08 to 0.19 mmol/L, respectively. The lecithin:cholesterol acyltransferase (LCAT) activity and cholesterol esterification rate were Ͻ40% of normal control values. LCAT mass was Ϸ50% of normal control. Sequence analysis of polymerase chain reaction-amplified DNA of the proband's apoA-I gene showed a homozygous T-to-A transition resulting in the substitution of Val 156 with Glu (apoA-I Oita). Direct sequencing of samples obtained from other family members showed that the brother was homozygous, whereas the son was a heterozygous carrier of apoA-I Oita. The heterozygote for apo A-I Oita showed nearly 60% of normal apoA-I and normal HDL cholesterol levels. In vivo turnover studies in rabbits demonstrated that the variant apoA-I was rapidly cleared from plasma compared with normal human apoA-I. Our data suggest that the Val156Glu substitution is associated with apoA-I and HDL deficiency, partial LCAT deficiency, and corneal opacities and that Val156 of apoA-I may play an important role in apoA-I function. (Arterioscler Thromb Vasc Biol. 1998;18:389-396.)
A polipoprotein A-I is composed of 243 amino acid residues that fold into amphipathic helixes, thus forming functional domains. ApoA-I plays a leading role in HDL-mediated cholesterol efflux from peripheral cells and acts as a cofactor for LCAT activation. 1 The functional domains of apoA-I have been recently examined by using monoclonal anti-apoA-I antibodies, mutagenized apoA-I, and immunochemical and physicochemical approaches. 1, 2 In addition, naturally occurring mutations in the apoA-I gene have been structurally and functionally characterized to be the underlying molecular defects of low HDL levels. [3] [4] [5] These data suggest that the functional domains of apoA-I contain central amphipathic ␣-helixes involving amino acid residues between 137 and 186, which are critical for both activation of LCAT and enhancing cholesterol efflux from peripheral cells.
More than 10 apoA-I gene defects of either a deletion or insertion leading to HDL deficiency have been reported. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, in subjects with HDL deficiency, CAD is not always present. In addition, Ϸ40 heterozygous structural apoA-I variants with a single amino acid substitution have been characterized. 2,16 -21 However, most of these variants do not affect HDL concentration except for nine that are associated with reduced plasma apoA-I and HDL cholesterol levels. [17] [18] [19] [20] [21] [22] [23] [24] [25] In this article we report a novel, homozygous, missense point mutation in the apoA-I gene that is associated with apoA-I and HDL deficiencies, corneal opacities, and CAD.
Methods Subjects
A 67-year-old Japanese man was admitted to Oita Prefectural Hospital because of worsening effort-dependent chest oppression, which was first experienced 3 months before admission. His body mass index was 27.5 kg/m 2 . He had smoked 50 cigarettes per day for 50 years. Physical examination showed bilateral corneal opacities, and the blood pressure was 130/70 mm Hg. There was no tonsillar hypertrophy, tendinous xanthomata, hepatosplenomegaly, or peripheral neuropathy. Serum concentrations of apoA-I and HDL cholesterol were markedly low (2.9 to 7.3 mg/dL and 0.08 to 0.19 mmol/L, respectively). Other laboratory findings were within the normal range. A coronary arteriogram showed 90% stenosis of the left main trunk and 75% stenosis of the proximal portion of the left anterior descending artery and circumflex artery. Aortocoronary bypass surgery was performed. Complete occlusion of the left internal carotid artery, stenosis of the right proximal internal carotid artery, complete occlusion of the left vertebral artery, and stenosis of the right vertebral artery were also detected on angiography. The pedigree for the proband is shown in Fig 1. Examination of other family members showed that the brother (II 1) also had bilateral corneal opacities, but neither the proband's son (III 1) nor his grandchildren (IV 1,2) had corneal opacities. The proband's elder brother (II 1) had no history of diabetes mellitus or hypertension or any symptom suggestive of CAD, and he also had a normal resting electrocardiogram. The proband's son (III 1) did not suffer from clinical symptoms or signs of CAD, and he had a normal resting and stress electrocardiogram. The proband's parents had died at 83 and 82 years of age. This study was approved by the Ethics Review Committee of the School of Medicine, Fukuoka University. The proband and his family members gave their informed consent prior to their participation in this study.
Lipid, Apolipoprotein, and Lipoprotein Analyses
Blood samples were collected in tubes containing disodium EDTA after a 12-hour fast. Plasma concentrations of cholesterol and TG were determined by an enzymatic method. Apolipoprotein concentrations were measured by single radial immunodiffusion, and plasma lipoproteins were separated by sequential ultracentrifugation. 5 The following density fractions were obtained: VLDL (dϽ1.006 g/mL), LDL (dϭ1.019 to 1.063 g/mL), HDL 2 (dϭ1.063 to 1.125 g/mL), and HDL 3 (dϭ1.125 to 1.21 g/mL). Fractionation of plasma lipoproteins by Superose 6HR 10/30 gel chromatography was performed with a fast protein liquid chromatography system (Pharmacia Fine Chemicals). The column matrix was equilibrated with PBS containing 1 mmol/L EDTA and 0.02% NaN 3 (pH 7.4). Fifty 0.5-mL fractions were collected at a flow rate of 0.5 mL/min. Electrophoresis of lipoproteins from the different plasma density fractions was performed by 12.5% SDS-PAGE, and the distribution of apoA-I was visualized with an ECL Western blotting kit (Amersham Life Science). Control samples for comparing plasma concentrations of lipids, lipoproteins, LCAT activity, and LCAT mass were obtained from healthy volunteers matched for age and sex. Informed consent was obtained from all control subjects.
Electrophoresis and Immunoblotting
IEF gel electrophoresis on a pH gradient from 4 to 6 using plasma samples from the proband and his family was performed as described previously. 26 In brief, 1 L plasma was incubated at room temperature for 1 hour with 30 L of 10 mmol/L Tris HCl (pH 8.2) containing 1% sodium decyl sulfate, 2% ampholytes (pH 4 to 6), and 10% ␤-mercaptoethanol. The mini-slab gel system (Biometra-Multigel G-44, Biometra) with a 7.2% polyacrylamide gel containing 5 mol/L urea and 2% ampholytes (pH 4 to 6) was used for IEF. A twodimensional gel electrophoresis of plasma, consisting of IEF followed by SDS-PAGE, was performed as described previously. 11 The apoA-I bands were identified by immunoblots with a polyclonal rabbit anti-human apoA-I antiserum.
Isolation of ApoA-I
HDLs (dϭ1.063 to 1.21 g/mL) were isolated from a 50-mL plasma sample from the proband and from a normal, healthy subject by preparative ultracentrifugation, delipidated, and then solubilized in deionized water. 26 Delipidated HDL was passed through a gel chromatography column on Sephacryl S-200. Variant apoA-I and normal apoA-I were isolated by Immobiline IEF, with a pH gradient ranging from 5 to 6 as described previously.
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Iodination of ApoA-I
Labeling of normal human apoA-I and apoA-I Oita with Na[
125 I] (Du Pont-New England Nuclear) was carried out according to the iodine monochloride method of McFarlane. 27 The labeled apoA-I was dialyzed at 4°C for 40 hours against 0.15 mol/L NaCl containing 0.3 mmol/L EDTA, pH 7.4. The specific activity of labeled apoA-I ranged from 350 to 450 counts per minute per nanogram protein, and 99% of the radioactivity in labeled apoA-I could be precipitated by trichloroacetic acid. Before the turnover studies, labeled apoA-I was passed through a 0.45-m filter with the addition of bovine albumin (fatty acid free, Sigma Chemical Co) to a final concentration of 10 mg/mL and stored for 1 to 2 days at 4°C.
In Vivo Turnover Study of ApoA-I
Male Japanese White rabbits (body weight, 2.5 to 3.0 kg) were purchased from Kyudo Co, Fukuoka, Japan. The animals were housed individually in a 12-hour/12-hour light/dark cycle environment and provided with a commercial diet and water ad libitum. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of our institution. The procedures of in vivo turnover studies were performed essentially as described previously. 28 In brief, 2 days before and throughout the entire turnover study, five drops of saturated KI were added each day to the drinking water. Twenty-five Ci of 125 I-labeled apoA-I in 1 mL saline with 10 mg/mL bovine albumin was injected into each animal via the marginal ear vein. Blood samples were collected via the marginal ear vein at 5 minutes and at 3, 6, 9, and 24 hours after injection and then once a day for 6 days. The FCR was calculated as described by Matthews. 29 The clearance of each labeled apoA-I was measured in four different rabbits.
Haplotype Analysis
We determined the apoE genotype by using HhaI digestion of the apoE gene after amplification by PCR as reported by our laboratory. 30 ApoA-I MspI and apoC-III SstI polymorphisms were performed as previously reported.
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Nondenaturing Gradient PAGE HDL particle sizes were determined by nondenaturing gradient PAGE on 4% to 30% gels (Pharmacia LKB Biotechnology). 32 Plasma with a dϽ1.21g/mL was obtained by ultracentrifugation at 100 000 rpm for 2 hours (Beckman TL-100 ultracentrifuge). This was followed by the addition of 20 g protein to the gel. Protein was visualized with 0.05% Coomassie brilliant blue G-250, and then the gel was scanned with a personal densitometer SI (Molecular Dynamics Inc). The gel was calibrated with a standard protein mixture (high-molecularweight calibration kit, Pharmacia LKB Biotechnology). HDL particles size was calculated from the calibration curve of the peak migration distance versus that of the standard.
CER, LCAT Activity, and LCAT Mass Measurements
CER indicates the esterification of endogenous cholesterol, which was determined by the method of Stokke and Norum. 33 LCAT activity was measured by using a proteoliposome as a substrate. 34 LCAT mass was kindly assayed by Prof John J. Albers, University of Washington, Department of Medicine, Northwest Lipid Research Laboratories, Seattle, Wash.
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DNA Amplification by PCR
Genomic DNA was isolated from 120 L peripheral blood as described in the Genomix kit manual (Talent srI). Ten microliters of this extract was used as a template for PCR. Oligonucleotide primers 
Selected Abbreviations and Acronyms
CAD ϭ coronary artery disease CER ϭ cholesterol esterification rate FCR ϭ fractional catabolic rate IEF ϭ isoelectric focusing LCAT ϭ lecithin:cholesterol acyltransferase PAGE ϭ polyacrylamide gel electrophoresis PCR ϭ polymerase chain reaction TG ϭ triglyceride for the apoA-I gene were synthesized on the basis of published data (model 380B DNA synthesizer, Applied Biosystems). The primers for the apoA-I gene are listed in Table 1 . PCR was performed according to the protocol published by the manufacturer with the use of a Perkin Elmer-Cetus thermal cycler. Amplification was performed by initial denaturation at 96°C for 10 minutes, followed by 30 cycles at 96°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute, and a final extension for 7 minutes at 72°C. A reaction volume of 100 L contained 2.5 U Taq polymerase (Perkin Elmer-Cetus), 150 ng genomic DNA, 20 pmol of each primer, and 200 mol of each dNTP in 10ϫ reaction buffer containing 0.1 mol/L Tris HCl, pH 8.3, 0.5 mol/L KCl, 15 mmol/L MgCl 2 , and 0.1% (wt/vol) gelatin, as described previously.
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DNA Sequence Analysis
The PCR-amplified DNA products were purified with a GeneClean kit (Bio101), and purified DNA fragments were ligated to the pT7Blue-T vector (Novagen). Twelve clones of both strands in opposite directions were sequenced by the dideoxy chain-termination method using Sequenase (US Biochemical). 37 The DNA fragment around the mutation in exon 4 of apoA-I was amplified and subjected to direct sequencing by using a DNA sequencing kit (dye terminator cycle sequencing ready reaction, Perkin Elmer) with an ABI 373 DNA sequencer.
Statistical Analysis
Data are expressed as meanϮSD. Differences in FCR in the turnover study were evaluated for statistical significance by Student's t test. A value of P Ͻ.05 denoted statistical significance.
Results
DNA Sequence Analysis
Three pairs of oligonucleotide primers were used to amplify exons and exon-intron boundaries of the apoA-I gene by PCR. Nucleotide numbers were based on the published sequence for apoA-I DNA. 36 Fig 2A shows an autoradiogram of the sequencing results around region 1762 in exon 4 of the apoA-I gene. A T-to-A substitution was detected at position 1762 of exon 4 in all 12 clones of the subcloned DNA fragment from the proband, resulting in a single amino acid change (Glu for Val) at residue 156. Since this substitution has not been previously reported, we termed this apoA-I variant (Val156Glu) "apoA-I Oita" owing to the residence of the proband. Other parts of the apoA-I gene were identical to the wild type, except for a Ϫ75 G-to-A variation in the promoter region. Further direct sequence analysis showed that the brother of the proband was also homozygous for apoA-I Oita, whereas the proband's son was heterozygous ( Fig 2B) ; however, the two grandchildren did not carry this mutant allele.
Lipid, Apolipoprotein, and Lipoprotein Profiles
The concentrations of lipids, lipoproteins, and apolipoproteins in members of the family with apoA-I Oita are shown in Tables 2 and 3 . The concentrations of total cholesterol, TG, and LDL cholesterol in the proband were within normal levels. The free cholesterol-to-total cholesterol ratio in the proband was slightly higher in the total, VLDL, and LDL fractions but threefold higher in the HDL fraction than those of nonaffected family members, indicating that esterification of cholesterol was reduced mainly in the HDL fraction (Table 4) . The proband and his brother had Ͻ10% and Ͻ15%, respectively, of normal apoA-I and HDL cholesterol levels. The proband's son had nearly 60% of normal apoA-I and HDL cholesterol levels, whereas these two parameters were normal in other family members. Although cholesterol concentrations in both HDL 2 and HDL 3 subfractions were markedly reduced, the degree of reduction in the HDL 2 subfraction was higher than that in HDL 3 in either homozygotes or heterozygotes. Plasma lipoproteins separated by gel chromatography from the proband showed a rearrangement of TGs among plasma lipoproteins (Fig 3) . The TG of the proband was distributed mainly in the LDL fraction instead of in VLDL, a characteristic similar to that of normal control subjects. The cholesterol level in the HDL fraction was markedly reduced, whereas TG was only slightly decreased. The distribution of apoA-I was shifted to a higher density fraction of HDL (Fig 3) . ApoC-II and apoC-III were at moderately low levels in the homozygote, whereas apoB and apoE concentrations were within the normal range. ApoE genotype was E3/E3 in all family members tested in the present study. 
Plasma CER, LCAT Activity, and LCAT Mass
Analysis of CER, LCAT activity, and LCAT mass showed that these parameters were Ϸ50% lower in homozygous apoA-I Oita carriers than in normal control subjects but were not different from those in heterozygous carriers (Table 5 ). These data indicate that the partial reductions in LCAT activity and mass in this case may be secondary to a Val156Glu substitution in apoA-I rather than a defect in the LCAT gene itself.
Electrophoresis and Immunoblots
IEF of plasma at a pH range of 4 to 6 followed by immunoblotting showed no apoA-I-4 band in the proband (II 2) or his brother (II 1) but rather showed apoA-I-3 and apoA-I-5 bands. In contrast, a plasma sample from the proband's son (III 1) showed apoA-I-2, apoA-I-4, and faint apoA-I-3 and apoA-I-5 bands (Fig 4) . Two-dimensional electrophoresis (IEF and SDS) followed by immunoblotting showed that the molecular weights of apoA-I-3 and apoA-I-5 bands of the proband were similar to that of normal apoA-I (data not shown). The nondenaturing gradient gel electrophoresis of HDL particles followed by scanning with a personal densitometer SI is shown in Fig 5. In the homozygous proband (II 2), the HDL fraction was hardly observed. In the heterozygote (III 1), HDL particle size was smaller than that in normal control subjects.
Haplotype Analysis
The results of apoC-III SstI, apoA-I MspI, and apoA-I promoter (Ϫ75G/A) polymorphisms are shown in Table 3 . Haplotypes S1S1, M1M1, and AA were observed in both the proband (II 2) and his brother (II 1). The distribution pattern of these three markers in the apoA-I Oita family was compatible with that of an apoA-I Oita mutant allele in the pedigree.
In Vivo ApoA-I Kinetic Study
Plasma decay curves of 125 I-labeled normal and variant apoA-I in rabbits are shown in Fig 6. The turnover of 125 I-labeled apoA-I Oita was markedly faster than that of 125 I-labeled normal human apoA-I. The mean FCR of 125 I-labeled apoA-I Oita was more than double that of 125 I-labeled normal human apoA-I (Table 6 ).
Discussion
The major finding of the present study was the identification of a novel, homozygous, missense point mutation, apoA-I (Val156Glu) Oita, in exon 4 of the apoA-I gene that was found to be associated with markedly low levels of apoA-I and HDL cholesterol, partial LCAT deficiency, corneal opacities, and CAD. The plasma concentrations of apoA-I and HDL cholesterol in the homozygous apoA-I Oita subjects were Ͻ15% of those in normal control subjects but were Ϸ60% of the control values in the heterozygote. We also observed a gene-dosage effect of the apoA-I Oita mutant allele on apoA-I and HDL cholesterol levels in this family. More than 10 cases of homozygous apoA-I defects caused by a nonsense mutation, a deletion, and an insertion have been reported to be associated with apoA-I and HDL deficiency. The clinical manifestation in these cases was variable and included premature atherosclerosis, xanthomatosis, and corneal opacities. Premature CAD was clearly reported in only four cases. 6 -8,13 In contrast, Ϸ40 structural apoA-I variants have been reported, although most of them are not associated with changes in HDL level or premature CAD except for nine cases. [17] [18] [19] [20] [21] [22] [23] [24] [25] The reason for this phenomenon remains unclear, but it may be partly related to the fact that almost all patients with apoA-I variants characterized so far have been heterozygotes. Thus, these apoA-I variants have little dominant effect on lipoproteins metabolism in vivo. To our knowledge, a homozygous, missense point mutation in the apoA-I gene that is associated with clinical manifestations has not yet been reported. ApoA-I (Glu136Lys) was the first reported case of homozygosity for a structural apoA-I variant. 38 However, this apoA-I variant was not correlated with either HDL level or any clinical complication. Therefore, apoA-I (Val156Glu) Oita is the first well-documented report correlating homozygosity for an apoA-I variant with reduced HDL concentrations.
The mechanisms by which the apoA-I (Val156Glu) substitution in homozygosity influences HDL metabolism and results in clinical complications are probably complex. In vitro experiments with monoclonal antibodies and mutagenized apo A-I suggest that residues 143 to 164 of apoA-I are involved in the LCAT activation process. 1, 39 A naturally occurring mutation, apoA-I Seattle, with a deletion from Glu146 to Arg160, in heterozygosity was reported to be associated with a reduction in apoA-I and HDL cholesterol levels to below 15% of control values. 11 Four of six reported heterozygosities for apoA-I variants in this domain with a dominant effect on HDL metabolism are associated with reduced LCAT cofactor activity or LCAT activity per se. ApoA-I (Pro143Arg) Giessen has been isolated from plasma, and LCAT cofactor activity of the variant has been demonstrated to be Ϸ60% to 70% of that in control apoA-I. 22 In another study, isolated apoA-I (Pro165Arg) from the proband's plasma was reconstituted into artificial discoidal HDL. The apoA-I (Pro165Arg) variant exhibited Ϸ30% to 70% of LCAT cofactor activity compared with that of normal apoA-I. 40 Low LCAT activity was also reported in apoA-I (Arg151Cys) Paris and apoA-I (Arg160Leu) Oslo. 20, 21 These data indicate the important role of residues 143 to 164 in apoA-I function, particularly the LCAT activation process. The reduced CER, LCAT activity, and LCAT mass but normal LCAT specific activity observed in the apoA-I Oita homozygote indicates a partial LCAT deficiency. The reduced LCAT activity in the apoA-I Oita homozygote is consistent with the elevated free cholesterolto-total cholesterol ratio observed in the HDL fraction. Because the substitution of Val for Glu at residue 156 is positioned within residues 143 to 164 of apoA-I, partial LCAT deficiency in the present case is secondary to this substitution and in part is the cause of low plasma HDL levels observed in patients with apoA-I Oita.
Recently, the central amphipathic ␣-helixes have been identified as the functional domains for cholesterol efflux. Monoclonal antibodies with epitopes recognizing amino acid residues 149 to 186 of apoA-I reduce the binding of reconstituted HDL to Hela cells and of cholesterol efflux from adipocytes. 41 On the other hand, the naturally occurring heterozygous apoA-I (Pro165Arg) variant failed to promote cellular cholesterol efflux in murine adipocytes and peritoneal macrophages. 42 These in vitro studies suggest that central A, Samples from a normal subject; B, sample from the proband of apoA-I Oita. TG (F) and cholesterol (E) contents of each fraction were measured enzymatically. In the inset each lipoprotein fraction was subjected to 12.5% SDS-PAGE followed by Western blotting. amphipathic ␣-helixes of apoA-I contain several discontinuous, specific regions responsible for the efflux of cellular cholesterol, probably by selectively interacting with the cell surface binding sites. Because apoA-I Oita is located within epitopes of monoclonal antibodies that inhibit cellular cholesterol efflux by apoA-I, apoA-I Oita may be associated with impaired efflux of cellular cholesterol. Hence, low levels of HDL cholesterol in the apoA-I Oita proband may be associated with impaired cholesterol efflux from cells. Brinton et al 43 have recently demonstrated that the level of plasma apoA-I in humans is mainly determined by the FCR of apoA-I. More recently, Miettinen and coworkers 19 showed that the presence of apoA-I (Leu159Arg) Fin was associated with markedly reduced concentrations of plasma apoA-I and HDL cholesterol and increased catabolism of apoA-I in affected heterozygous subjects. They speculated that the moderate hypertriglyceridemia in affected subjects with apoA-I (Leu159Arg) Fin may have contributed to the increased apoA-I FCR and markedly reduced concentration of serum HDL cholesterol. Increased catabolism of apoA-I was also observed in apoA-I (Arg173Cys) Milano, apoA-I (Arg26Gly) Iowa, apoA-I (Lys10730), and in subjects with low HDL cholesterol concentrations. [43] [44] [45] [46] Turnover studies of isolated apoA-I Milano showed an increased catabolism of the variant apoA-I due to heterodimerization or homodimerization of mutant apoA-I. On the other hand, apoA-I Iowa was shifted to a higher density HDL fraction (HDL 3 and dϾ1.21 g/mL), whereas the turnover of apoA-I Iowa was faster than that of normal apoA-I in the high-density HDL fraction. In the present case, the distribution of the proband's apoA-I was shifted to a higher density lipoprotein fraction, and gradient gel electrophoresis of HDL particles indicated that HDL particle size was smaller in the apoA-I Oita heterozygote than in normal control subjects. We isolated variant apoA-I Oita from the plasma of the proband and studied its turnover rate in rabbits. The turnover study demonstrated that apoA-I Oita has an accelerated catabolic rate in rabbits compared with normal human apoA-I. The shift of apoA-I to a higher density HDL fraction in the proband with apoA-I Oita may be related to faster catabolism of apoA-I, which may contribute to apoA-I deficiency and low HDL cholesterol levels in our patient.
In the present study, plasma TG of the apoA-I Oita proband was observed mainly in the LDL fraction. A high TG content in the LDL fraction was also observed in Tangier disease and in subjects homozygous for apoA-I (Glu136Lys). 38, 47 Enrichment of TG in the LDL fraction indicates an imbalance of lipid exchange with HDL.
A common genetic polymorphism (Ϫ75 G/A) in the apoA-I promoter region was found in the apoA-I Oita proband (II 2) as well as his brother (II 1) and son (III 1). Although previous studies about the impact of the Ϫ75 G-to-A mutation in the apoA-I promoter region on HDL cholesterol or apoA-I level are controversial, more recent investigations in genetically homogeneous populations have indicated that the G-to-A mutation does not have a significant direct effect on plasma HDL cholesterol or apoA-I level. 48, 49 Thus, the presence of the Ϫ75 G/A polymorphism in the apoA-I Oita family is probably not related to low plasma HDL cholesterol levels in this case. Control values represent meanϮSD and (number of subjects).
In conclusion, we analyzed a novel, homozygous, missense point mutation in the apoA-I gene. The Val156Glu substitution in exon 4 of the apoA-I gene in both alleles has a serious impact on HDL metabolism, leading to apoA-I and HDL deficiencies, partial LCAT deficiency, and corneal opacities. The proband also presented with clinical features of arteriosclerosis affecting the coronary, carotid, and vertebral arteries. However, the proband's elder brother, who was homozygous for apoA-I Oita, did not have any symptoms suggestive of CAD. Moreover, the proband had other coronary risk factors apart from his apoA-I deficiency, such as age, smoking, and obesity. Because this family study was limited, the impact of this disorder on coronary atherosclerosis remains unknown at present. Further large-scale family studies are necessary to answer this issue. Nevertheless, the unique case presented in this study provides a good opportunity to understand the structure-function relationship between apoA-I and HDL metabolism. 
